ATE161270T1 - Aufklärung und synthese von ausgewählten pentapeptiden - Google Patents

Aufklärung und synthese von ausgewählten pentapeptiden

Info

Publication number: ATE161270T1
Authority: AT; Austria
Prior art keywords: pentapeptides; dolastatin; chem; peptides; elucidation
Prior art date: 1993-01-26

Application number

AT94300495T

Other languages

English (en)

Inventor

George R Pettit

Jayaram K Srirangam

Original Assignee

Univ Arizona

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-26

Filing date

1994-01-24

Publication date

1998-01-15

1994-01-24 Application filed by Univ Arizona filed Critical Univ Arizona

1998-01-15 Application granted granted Critical

1998-01-15 Publication of ATE161270T1 publication Critical patent/ATE161270T1/de

Links

230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 abstract 2
OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 abstract 2
108010045524 dolastatin 10 Proteins 0.000 abstract 2
108090000765 processed proteins & peptides Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
241000237373 Aplysia sp. Species 0.000 abstract 1
241000237378 Dolabella auricularia Species 0.000 abstract 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000008878 coupling Effects 0.000 abstract 1
238000010168 coupling process Methods 0.000 abstract 1
238000005859 coupling reaction Methods 0.000 abstract 1
230000009897 systematic effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Crystallography & Structural Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT94300495T 1993-01-26 1994-01-24 Aufklärung und synthese von ausgewählten pentapeptiden ATE161270T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/009,296 US5780588A (en)	1993-01-26	1993-01-26	Elucidation and synthesis of selected pentapeptides

Publications (1)

Publication Number	Publication Date
ATE161270T1 true ATE161270T1 (de)	1998-01-15

Family

ID=21736778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94300495T ATE161270T1 (de)	1993-01-26	1994-01-24	Aufklärung und synthese von ausgewählten pentapeptiden

Country Status (6)

Country	Link
US (1)	US5780588A (de)
EP (1)	EP0612762B1 (de)
JP (1)	JPH08119990A (de)
AT (1)	ATE161270T1 (de)
CA (1)	CA2114156C (de)
DE (1)	DE69407322T2 (de)

Families Citing this family (769)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0731106B1 (de) *	1993-10-01	2004-11-17	Teikoku Hormone Mfg. Co., Ltd.	Dolastatin-derivate
CA2298639C (en) *	1997-09-24	2005-07-05	Erik J. Flahive	Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6686445B1 (en)	1997-09-24	2004-02-03	Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University	Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
EP2266607A3 (de)	1999-10-01	2011-04-20	Immunogen, Inc.	Immunokonjugate für Krebsbehandlung
US6884869B2 (en) *	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US7256257B2 (en) *	2001-04-30	2007-08-14	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
EP1392359B2 (de)	2001-05-11	2013-03-13	Ludwig Institute for Cancer Research Ltd.	Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en)	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
DK2357006T3 (en)	2002-07-31	2015-12-21	Seattle Genetics Inc	Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
EP2289559B1 (de)	2003-02-20	2014-02-12	Seattle Genetics, Inc.	Anti-CD70-Antikörper-Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs und Immunerkrankungen
NZ583292A (en)	2003-11-06	2012-03-30	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
EP1791565B1 (de)	2004-09-23	2016-04-20	Genentech, Inc.	Zystein-modifizierte Antikörper und Konjugate
CA2586909A1 (en) *	2004-11-12	2006-12-14	Seattle Genetics, Inc.	Auristatins having an aminobenzoic acid unit at the n terminus
AU2005322410B2 (en)	2004-11-30	2011-11-10	Amgen Fremont Inc.	Antibodies directed to GPNMB and uses thereof
FR2883873B1 (fr)	2005-03-31	2009-07-10	Pharmamens Sarl	Inhibiteurs d'age
US8067546B2 (en)	2005-04-19	2011-11-29	Seattle Genetics, Inc.	Humanized anti-CD70 binding agents and uses thereof
EP1917020B1 (de)	2005-07-07	2016-05-25	Seattle Genetics, Inc.	Monomethylvalin-verbindungen mit phenylalanin-seitenketten-modifikationen am c-terminus
US8871720B2 (en) *	2005-07-07	2014-10-28	Seattle Genetics, Inc.	Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
PL1912671T3 (pl)	2005-07-18	2018-02-28	Seattle Genetics, Inc.	Koniugaty beta-glukuronid-linker-lek
EP2623516B1 (de)	2005-12-02	2015-07-15	Genentech, Inc.	Zusammensetzungen und Verfahren für die Behandlung von Krankheiten und Störungen in Zusammenhang mit der Zytokinsignalisierung, mit Antikörper, die an IL-22 und IL-22R bind.
CA2633887C (en)	2005-12-15	2015-12-22	Genentech, Inc.	Methods and compositions for targeting polyubiquitin
RU2450020C2 (ru)	2006-01-05	2012-05-10	Дженентек, Инк.	АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
DK1976884T3 (da)	2006-01-20	2013-02-25	Genentech Inc	Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
US7750116B1 (en) *	2006-02-18	2010-07-06	Seattle Genetics, Inc.	Antibody drug conjugate metabolites
AR059851A1 (es)	2006-03-16	2008-04-30	Genentech Inc	Anticuerpos de la egfl7 y metodos de uso
PL2032606T3 (pl)	2006-05-30	2014-04-30	Genentech Inc	Przeciwciała i immunokoniugaty oraz ich zastosowania
US7910108B2 (en) *	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008033782A2 (en)	2006-09-12	2008-03-20	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
NZ576132A (en)	2006-10-27	2012-04-27	Genentech Inc	Antibodies and immunoconjugates and uses therefor
EP2099823B2 (de)	2006-12-01	2022-02-09	Seagen Inc.	Verschiedene zielmoleküle bindende mittel und ihre verwendung
US9090693B2 (en)	2007-01-25	2015-07-28	Dana-Farber Cancer Institute	Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
NZ578701A (en)	2007-02-09	2012-02-24	Genentech Inc	Anti-robo4 antibodies and uses therefor
CN101688229B (zh)	2007-03-15	2013-06-12	路德维格癌症研究所	包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CA2683568A1 (en)	2007-05-08	2008-11-20	Genentech, Inc.	Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US9845355B2 (en)	2007-07-16	2017-12-19	Genentech, Inc.	Humanized anti-CD79b antibodies and immunoconjugates and methods of use
RU2511410C3 (ru)	2007-07-16	2021-06-15	Дженентек, Инк.	АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2609915T3 (es)	2007-08-14	2017-04-25	Ludwig Institute For Cancer Research Ltd.	Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
SG193868A1 (en)	2007-09-26	2013-10-30	Chugai Pharmaceutical Co Ltd	Modified antibody constant region
ES2908934T3 (es)	2007-10-04	2022-05-04	Zymogenetics Inc	ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
HUE031533T2 (hu)	2007-10-19	2017-07-28	Seattle Genetics Inc	CD19-kötõszerek valamint alkalmazásuk
EP3115469B1 (de)	2007-11-19	2020-04-29	Celera Corporation	Lungenkrebsmarker und verwendungen davon
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
CA2713504A1 (en)	2008-01-31	2009-08-13	Genentech, Inc.	Anti-cd79b antibodies and immunoconjugates and methods of use
EP2842575B1 (de)	2008-03-18	2017-09-27	Seattle Genetics, Inc.	Auristatin mit einem Heilmittel bindenden Konjugat
KR20100131003A (ko) *	2008-03-31	2010-12-14	제넨테크, 인크.	천식을 치료 및 진단하기 위한 조성물 및 방법
SI2279412T1 (sl)	2008-04-09	2017-10-30	Genentech, Inc.,	Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
CA2723197C (en)	2008-05-02	2017-09-19	Seattle Genetics, Inc.	Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
DK2318832T3 (da)	2008-07-15	2014-01-20	Academia Sinica	Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
WO2010039832A1 (en)	2008-10-01	2010-04-08	Genentech, Inc.	Anti-notch2 antibodies and methods of use
UA109633C2 (uk)	2008-12-09	2015-09-25		Антитіло людини проти тканинного фактора
WO2010108127A1 (en)	2009-03-20	2010-09-23	Genentech, Inc.	Bispecific anti-her antibodies
HRP20150965T1 (hr) *	2009-03-25	2015-11-06	Genentech, Inc.	Anti-fgr3 protutijela i metode koje ih koriste
AR075925A1 (es)	2009-03-25	2011-05-04	Genentech Inc	Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
TW201038286A (en)	2009-04-01	2010-11-01	Genentech Inc	Anti-FcRH5 antibodies and immunoconjugates and methods of use
JP5501439B2 (ja)	2009-04-02	2014-05-21	ロシュグリクアートアクチェンゲゼルシャフト	完全長抗体と単鎖Ｆａｂフラグメントとを含む多重特異的抗体
KR20110138412A (ko)	2009-04-16	2011-12-27	애보트 바이오테라퓨틱스 코포레이션	항-ΤΝＦ-α 항체 및 그의 용도
EP2896404B1 (de)	2009-06-04	2017-08-02	Novartis AG	Verfahren zur Identifizierung von Stellen für IgG-Konjugation
ES2534355T3 (es)	2009-06-17	2015-04-21	Abbvie Biotherapeutics Inc.	Anticuerpos anti-VEGF y sus usos
WO2011005481A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
WO2011028952A1 (en)	2009-09-02	2011-03-10	Xencor, Inc.	Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
SG10201408401RA (en)	2009-09-16	2015-01-29	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
NZ599337A (en)	2009-10-22	2013-05-31	Genentech Inc	Anti-hepsin antibodies and methods using same
US8785600B2 (en)	2009-10-23	2014-07-22	Millennium Pharmaceuticals, Inc.	Anti-GCC antibody molecules and related compositions and methods
WO2011056497A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor type iib compositions and methods of use
WO2011056494A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en)	2009-10-26	2011-05-12	Genentech, Inc.	Bone morphogenetic protein receptor type ii compositions and methods of use
ES2639056T3 (es)	2009-10-28	2017-10-25	Abbvie Biotherapeutics Inc.	Anticuerpos anti-EGFR y sus usos
MX2012005168A (es)	2009-11-05	2012-06-08	Genentech Inc	Metodos y composicion para secrecion de polipeptidos heterologos.
SG10201408598XA (en)	2009-11-30	2015-02-27	Genentech Inc	Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
KR20120123299A (ko)	2009-12-04	2012-11-08	제넨테크, 인크.	다중특이적 항체, 항체 유사체, 조성물 및 방법
DK2510011T3 (en)	2009-12-09	2014-12-01	Inst Nat Santé Et De La Rech Médicale	MONOCLONAL ANTIBODIES BINDING B7H6 AND APPLICATIONS THEREOF
JP5677451B2 (ja)	2009-12-10	2015-02-25	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	優先的にヒトｃｓｆ１ｒ細胞外ドメイン４に結合する抗体及びそれらの使用
ES2565208T3 (es)	2009-12-11	2016-04-01	F. Hoffmann-La Roche Ag	Anticuerpos anti-VEGF-C y métodos de uso de los mismos
WO2011084496A1 (en)	2009-12-16	2011-07-14	Abbott Biotherapeutics Corp.	Anti-her2 antibodies and their uses
TW201130971A (en)	2009-12-23	2011-09-16	Genentech Inc	Anti-Bv8 antibodies and uses thereof
MX2012008884A (es)	2010-02-08	2012-08-31	Agensys Inc	Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b.
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
NZ601293A (en)	2010-02-23	2014-10-31	Genentech Inc	Compositions and methods for the diagnosis and treatment of tumor
EP2542588A1 (de)	2010-03-05	2013-01-09	F. Hoffmann-La Roche AG	Antikörper gegen menschliches csf-1r und deren verwendungen
KR101656548B1 (ko)	2010-03-05	2016-09-09	에프. 호프만-라 로슈 아게	인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
TW201134481A (en)	2010-03-12	2011-10-16	Abbott Biotherapeutics Corp	CTLA4 proteins and their uses
RU2587625C2 (ru)	2010-03-24	2016-06-20	Дженентек, Инк.	Анти-lrp6 антитела
AR080793A1 (es)	2010-03-26	2012-05-09	Roche Glycart Ag	Anticuerpos biespecificos
MX2012011112A (es)	2010-03-31	2012-10-15	Boehringer Ingelheim Int	Anticuerpos anti-cd40.
WO2011130332A1 (en)	2010-04-12	2011-10-20	Academia Sinica	Glycan arrays for high throughput screening of viruses
MX346731B (es)	2010-04-23	2017-03-30	Genentech Inc *	Producción de proteínas heteromultiméricas.
RU2636461C2 (ru)	2010-05-03	2017-11-23	Дженентек, Инк.	Композиции и способы для диагностики и лечения опухоли
RU2613886C2 (ru)	2010-06-03	2017-03-21	Дженентек, Инк.	Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
KR101839163B1 (ko)	2010-06-08	2018-03-15	제넨테크, 인크.	시스테인 조작된 항체 및 접합체
PL2580243T3 (pl)	2010-06-09	2020-05-18	Genmab A/S	Przeciwciała przeciwko ludzkiemu CD38
AU2011267106B2 (en)	2010-06-15	2015-05-14	Genmab A/S	Human antibody drug conjugates against tissue factor
KR101885388B1 (ko)	2010-06-18	2018-08-03	제넨테크, 인크.	항-Ａｘｌ 항체 및 사용 방법
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
US8637641B2 (en)	2010-07-29	2014-01-28	Xencor, Inc.	Antibodies with modified isoelectric points
BR112013002535A2 (pt)	2010-08-03	2019-09-24	F. Hoffmann - La Roche Ag	biomarcadores de leucemia linfocítica crônica (cll)
MX2013001267A (es)	2010-08-13	2013-04-10	Genentech Inc	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
KR101653030B1 (ko)	2010-08-13	2016-08-31	로슈 글리카트 아게	항-테나신-c a２ 항체 및 이의 사용 방법
EA034742B1 (ru)	2010-08-13	2020-03-16	Роше Гликарт Аг	Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
JP2013537966A (ja)	2010-08-31	2013-10-07	ジェネンテック，インコーポレイテッド	バイオマーカー及び治療の方法
US8637642B2 (en)	2010-09-29	2014-01-28	Seattle Genetics, Inc.	Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
US9228023B2 (en)	2010-10-01	2016-01-05	Oxford Biotherapeutics Ltd.	Anti-ROR1 antibodies and methods of use for treatment of cancer
JP5974012B2 (ja)	2010-10-05	2016-08-23	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
CN103561759B (zh)	2010-10-22	2016-10-12	西雅图遗传学公司	以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
EA201390669A1 (ru)	2010-11-10	2013-11-29	Дженентек, Инк.	Способы и композиции для иммунотерапии заболеваний нервной системы
EP2637692A4 (de)	2010-11-12	2014-09-10	Scott & White Healthcare	Antikörper gegen den endothelialen tumormarker 8
KR101615420B1 (ko)	2010-12-16	2016-04-26	제넨테크, 인크.	Th2 억제에 관한 진단 및 치료
MA34881B1 (fr)	2010-12-20	2014-02-01	Genentech Inc	Anticorps et immunoconjugués anti-mésothéline
JP2014511106A (ja)	2010-12-22	2014-05-08	ジェネンテック，インコーポレイテッド	抗ｐｃｓｋ９抗体及び使用方法
EP2655413B1 (de)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
JOP20210044A1 (ar)	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
WO2012092539A2 (en)	2010-12-31	2012-07-05	Takeda Pharmaceutical Company Limited	Antibodies to dll4 and uses thereof
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
AR085138A1 (es)	2011-02-04	2013-09-11	Genentech Inc	VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
US20140088019A1 (en)	2011-02-11	2014-03-27	Zyngenia, Inc.	Monovalent and Multivalent Multispecific Complexes and Uses Thereof
HUE041335T2 (hu)	2011-03-29	2019-05-28	Roche Glycart Ag	Antitest FC-variánsok
JP2014516511A (ja)	2011-04-07	2014-07-17	ジェネンテック，インコーポレイテッド	抗ｆｇｆｒ４抗体及び使用方法
RU2013150331A (ru)	2011-04-20	2015-05-27	Рош Гликарт Аг	СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
EP2699260B1 (de)	2011-04-20	2024-11-20	Genmab A/S	Bispezifische antikörper gegen her2
WO2012143523A1 (en)	2011-04-20	2012-10-26	Genmab A/S	Bispecifc antibodies against her2
CA2835203A1 (en)	2011-05-09	2012-11-15	University Of Virginia Patent Foundation	Compositions and methods for treating cancer
CA2833212C (en)	2011-05-12	2020-06-09	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
CN103889459B (zh)	2011-05-16	2018-04-24	皇家飞利浦有限公司	生物正交药物活化
TWI547500B (zh)	2011-05-16	2016-09-01	建南德克公司	Ｆｇｆｒ１促效劑及其使用方法
CN103890010B (zh)	2011-05-19	2017-04-19	法国国家健康医学研究院	抗‑人‑her3抗体及其用途
ES2704038T3 (es)	2011-05-24	2019-03-13	Zyngenia Inc	Complejos multiespecíficos multivalentes y monovalentes y sus usos
FI3415531T3 (fi)	2011-05-27	2023-09-07	Glaxo Group Ltd	Bcma:aa (cd269/tnfrsf17) sitovia proteiineja
TWI603741B (zh)	2011-06-10	2017-11-01	梅爾莎納醫療公司	蛋白質-聚合物-藥物共軛體
EP2723377B1 (de)	2011-06-22	2018-06-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-axl-antikörper und verwendungen damit
AU2012273954A1 (en)	2011-06-22	2014-01-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-Axl antibodies and uses thereof
US20130004484A1 (en)	2011-06-30	2013-01-03	Genentech, Inc.	Anti-c-met antibody formulations
UA117901C2 (uk)	2011-07-06	2018-10-25	Ґенмаб Б.В.	Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013022855A1 (en)	2011-08-05	2013-02-14	Xencor, Inc.	Antibodies with modified isoelectric points and immunofiltering
US20140363438A1 (en)	2011-08-17	2014-12-11	Genentech, Inc.	Neuregulin antibodies and uses thereof
KR101886983B1 (ko)	2011-08-23	2018-08-08	로슈 글리카트 아게	2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
BR112014004168A2 (pt)	2011-08-23	2017-12-12	Roche Glycart Ag	anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
BR112014005720A2 (pt)	2011-09-15	2017-12-12	Genentech Inc	método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
AR087918A1 (es)	2011-09-19	2014-04-23	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
MX2014002996A (es)	2011-09-23	2014-05-28	Roche Glycart Ag	Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
CA2848520C (en)	2011-09-29	2019-11-26	Seattle Genetics, Inc.	Intact mass determination of protein conjugated agent compounds
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
DK2766392T3 (da)	2011-10-10	2019-10-07	Xencor Inc	Fremgangsmåde til oprensning af antistoffer
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en)	2011-10-10	2020-12-01	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
MX355128B (es)	2011-10-14	2018-04-06	Genentech Inc	Péptidos inhibidores de bace1 y uso de los mismos para el tratamiento de enfermedades o trastornos neurológicos.
SI2766393T1 (sl)	2011-10-14	2018-10-30	F. Hoffmann-La Roche Ag	Protitelesa Anti-HtrA1 in postopki uporabe
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
EP2776051A4 (de)	2011-10-28	2015-06-17	Hoffmann La Roche	Therapeutische kombinationen und verfahren zur behandlung von melanomen
CN104066748A (zh)	2011-11-21	2014-09-24	霍夫曼-拉罗奇有限公司	抗c-met抗体的纯化
EP2791174B1 (de)	2011-12-15	2018-02-28	F. Hoffmann-La Roche AG	Antikörper gegen menschlichen csf-1r und deren verwendungen
CA3111357A1 (en)	2011-12-23	2013-06-27	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2802603A4 (de)	2012-01-09	2015-11-04	Scripps Research Inst	Ultralange komplementaritätsbestimmungsbereiche und verwendungen davon
US20150011431A1 (en)	2012-01-09	2015-01-08	The Scripps Research Institute	Humanized antibodies
JP2015506944A (ja)	2012-01-18	2015-03-05	ジェネンテック，インコーポレイテッド	Ｆｇｆ１９修飾薬を使用する方法
PE20141561A1 (es)	2012-01-18	2014-11-12	Genentech Inc	Anticuerpos anti-lrp5 y metodos de uso
WO2013109994A1 (en)	2012-01-20	2013-07-25	Sea Lane Biotechnologies, Llc	Surrobody cojugates
CN104105711B (zh)	2012-02-10	2018-11-30	弗·哈夫曼-拉罗切有限公司	单链抗体及其他异多聚体
SG11201404703WA (en)	2012-02-11	2014-09-26	Genentech Inc	R-spondin translocations and methods using the same
ES2676031T3 (es)	2012-02-15	2018-07-16	F. Hoffmann-La Roche Ag	Cromatografía de afinidad basada en el receptor Fc
WO2013130093A1 (en)	2012-03-02	2013-09-06	Genentech, Inc.	Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9156915B2 (en)	2012-04-26	2015-10-13	Thomas Jefferson University	Anti-GCC antibody molecules
AR090903A1 (es)	2012-05-01	2014-12-17	Genentech Inc	Anticuerpos e inmunoconjugados anti-pmel17
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
EP2849797B1 (de)	2012-05-15	2019-12-18	Concortis Biosystems, Corp	Wirkstoffkonjugate, konjugationsverfahren und verwendungen davon
US9522940B2 (en)	2012-05-23	2016-12-20	Pieris Pharmaceuticals Gmbh	Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
HUE043552T2 (hu)	2012-06-08	2019-09-30	Sutro Biopharma Inc	Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
CA2875096A1 (en)	2012-06-15	2013-12-19	Genentech, Inc.	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
EP3488870B1 (de)	2012-06-19	2024-03-20	Ambrx, Inc.	Anti-cd70-antikörper-arzneimittelkonjugate
EP2863955B1 (de)	2012-06-26	2016-11-23	Sutro Biopharma, Inc.	Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
MX2014014065A (es)	2012-06-27	2015-02-04	Hoffmann La Roche	Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
MX2014014804A (es)	2012-06-27	2015-02-12	Hoffmann La Roche	Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
HK1207864A1 (zh)	2012-06-27	2016-02-12	F. Hoffmann-La Roche Ag	用於选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
BR112014030844A2 (pt)	2012-07-04	2019-10-15	Hoffmann La Roche	anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
MX353951B (es)	2012-07-04	2018-02-07	Hoffmann La Roche	Anticuerpos de anti-teofilina y metodos de uso.
WO2014006124A1 (en)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Covalently linked antigen-antibody conjugates
EP3632462A1 (de)	2012-07-06	2020-04-08	Genmab B.V.	Dimerprotein mit dreifacher mutation
SG10201605703TA (en)	2012-07-06	2016-09-29	Genmab Bv	Dimeric protein with triple mutations
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AU2013306098A1 (en)	2012-08-18	2015-02-12	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
UA118251C2 (uk)	2012-08-23	2018-12-26	Ейдженсіс, Інк.	Кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком 158p1d7
US9682934B2 (en)	2012-08-31	2017-06-20	Sutro Biopharma, Inc.	Modified amino acids
EP3211006A3 (de)	2012-09-19	2017-11-08	AbbVie Biotherapeutics Inc.	Varianten tnf alpha antikorper
WO2014056783A1 (en)	2012-10-08	2014-04-17	Roche Glycart Ag	Fc-free antibodies comprising two fab-fragments and methods of use
ES2937015T3 (es)	2012-11-01	2023-03-23	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Anticuerpo contra CD269 (BCMA)
AU2013343667A1 (en)	2012-11-08	2015-04-02	F. Hoffmann-La Roche Ag	HER3 antigen binding proteins binding to the beta-hairpin of HER3
US9284365B2 (en)	2012-11-13	2016-03-15	Genentech, Inc.	Anti-hemagglutinin antibodies and methods of use
EP2922574B1 (de)	2012-11-22	2023-05-17	Tagworks Pharmaceuticals B.V.	Chemisch spaltbare gruppe
CN105849086B (zh)	2012-11-24	2018-07-31	杭州多禧生物科技有限公司	亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
WO2014093394A1 (en)	2012-12-10	2014-06-19	Mersana Therapeutics, Inc.	Protein-polymer-drug conjugates
US10226535B2 (en)	2012-12-10	2019-03-12	Mersana Therapeutics, Inc.	Auristatin compounds and conjugates thereof
EP2931316B1 (de)	2012-12-12	2019-02-20	Mersana Therapeutics, Inc.	Hydroxylpolymer-heilmittelproteinkonjugate
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
US20150353636A1 (en)	2013-01-10	2015-12-10	Genmab B.V.	Human igg1 fc region variants and uses thereof
US10487155B2 (en)	2013-01-14	2019-11-26	Xencor, Inc.	Heterodimeric proteins
US10968276B2 (en)	2013-03-12	2021-04-06	Xencor, Inc.	Optimized anti-CD3 variable regions
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10131710B2 (en)	2013-01-14	2018-11-20	Xencor, Inc.	Optimized antibody variable regions
US9605084B2 (en)	2013-03-15	2017-03-28	Xencor, Inc.	Heterodimeric proteins
LT2943511T (lt)	2013-01-14	2019-11-11	Xencor Inc	Nauji heterodimeriniai baltymai
US9701759B2 (en)	2013-01-14	2017-07-11	Xencor, Inc.	Heterodimeric proteins
EP2945969A1 (de)	2013-01-15	2015-11-25	Xencor, Inc.	Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
HK1211235A1 (en)	2013-02-22	2016-05-20	霍夫曼-拉罗奇有限公司	Methods of treating cancer and preventing drug resistance
EP2961772A1 (de)	2013-02-26	2016-01-06	Roche Glycart AG	Anti-mcsp-antikörper
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
EA201591750A1 (ru)	2013-03-14	2016-05-31	Дженентек, Инк.	Антитела против b7-h4 и иммуноконъюгаты
HK1220916A1 (zh)	2013-03-14	2017-05-19	基因泰克公司	治疗癌症和预防癌症药物抗性的方法
MX374811B (es)	2013-03-15	2025-03-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
CN110433139A (zh)	2013-03-15	2019-11-12	艾伯维德国有限责任两合公司	抗egfr抗体药物偶联物制剂
CA2906022A1 (en)	2013-03-15	2014-09-25	Abbvie Inc.	Antibody drug conjugate (adc) purification
MA38495A1 (fr)	2013-03-15	2017-08-31	Genentech Inc	Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EP3936521B1 (de)	2013-03-15	2026-02-11	Xencor, Inc.	Heterodimere proteine
US10544187B2 (en)	2013-03-15	2020-01-28	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
WO2014144600A2 (en)	2013-03-15	2014-09-18	Viktor Roschke	Multivalent and monovalent multispecific complexes and their uses
EP2968537A1 (de)	2013-03-15	2016-01-20	Genentech, Inc.	Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
HK1220470A1 (zh)	2013-03-15	2017-05-05	Abbvie Biotechnology Ltd.	抗cd25抗体及其用途
US10519242B2 (en)	2013-03-15	2019-12-31	Xencor, Inc.	Targeting regulatory T cells with heterodimeric proteins
MX368665B (es)	2013-03-15	2019-10-10	Abbvie Biotherapeutics Inc	Variantes de fc.
RU2015144033A (ru)	2013-03-15	2017-04-26	Эббви Байотекнолоджи Лтд.	Антитела против cd25 и их применения
US10106624B2 (en)	2013-03-15	2018-10-23	Xencor, Inc.	Heterodimeric proteins
PL2972373T3 (pl)	2013-03-15	2020-03-31	F. Hoffmann-La Roche Ag	Biomarkery i sposoby leczenia stanów związanych z PD-1 i PD-L1
US10201614B2 (en)	2013-03-15	2019-02-12	Zymeworks Inc.	Cytotoxic and anti-mitotic compounds, and methods of using the same
AR095882A1 (es)	2013-04-22	2015-11-18	Hoffmann La Roche	Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2513405A (en)	2013-04-26	2014-10-29	Adc Biotechnology Ltd	Method of synthesising ADCs using affinity resins
US20160068613A1 (en)	2013-04-29	2016-03-10	Hoffmann-La Roche Inc.	Fc-receptor binding modified asymmetric antibodies and methods of use
EP4324480A3 (de)	2013-05-20	2024-05-08	F. Hoffmann-La Roche AG	Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
WO2014210397A1 (en)	2013-06-26	2014-12-31	Academia Sinica	Rm2 antigens and use thereof
EP3013347B1 (de)	2013-06-27	2019-12-11	Academia Sinica	Glykankonjugate und verwendung davon
WO2015006555A2 (en)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
CN111518199A (zh)	2013-07-18	2020-08-11	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
EP3747465A1 (de)	2013-07-31	2020-12-09	BioNTech AG	Diagnose und therapie von krebs mit krebsstammzellen
EP3027220A1 (de)	2013-08-01	2016-06-08	Agensys, Inc.	An cd37-proteine bindende antikörper-wirkstoffkonjugate (adc)
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
EP3041484B1 (de)	2013-09-06	2021-03-03	Academia Sinica	Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
AR097584A1 (es)	2013-09-12	2016-03-23	Hoffmann La Roche	Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US20150071923A1 (en)	2013-09-12	2015-03-12	Ge Wei	Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
RU2016109247A (ru)	2013-09-17	2017-10-19	Дженентек, Инк.	Способы применения антител к lgr5
KR102355745B1 (ko)	2013-10-11	2022-01-26	아사나 바이오사이언시스 엘엘씨	단백질-폴리머-약물 접합체
WO2015054658A1 (en)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3054987B1 (de)	2013-10-11	2019-10-09	The United States of America, represented by the Secretary, Department of Health and Human Services	Tem-8-antikörper und deren verwendung
ES2726850T3 (es)	2013-10-11	2019-10-09	Mersana Therapeutics Inc	Conjugados de proteína-polímero-fármaco
CU24320B1 (es)	2013-10-11	2018-02-08	Berlin Chemie Ag	Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
US10836821B2 (en)	2013-10-15	2020-11-17	Sorrento Therapeutics, Inc.	Drug-conjugates with a targeting molecule and two different drugs
WO2015057461A2 (en)	2013-10-18	2015-04-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that specifically bind ataxia telangiectasia-mutated and rad3-related kinase phosphorylated at position 1989 and their use
TWI658052B (zh)	2013-10-18	2019-05-01	美商建南德克公司	抗－ｒｓｐｏ抗體及使用方法
EP3066118B1 (de)	2013-11-06	2020-01-08	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
US10196455B2 (en)	2013-11-07	2019-02-05	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Neuregulin allosteric anti-HER3 antibody
HUE068207T2 (hu)	2013-11-21	2024-12-28	Genmab As	Antitest-drog konjugátumkészítmény
AR098743A1 (es)	2013-12-13	2016-06-08	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd33
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
MX2016008448A (es)	2013-12-27	2017-01-09	Zymeworks Inc	Conjugados de var2csa-farmaco.
EP3086815B1 (de)	2013-12-27	2022-02-09	Zymeworks Inc.	Sulfonamidhaltige verknüpfungssysteme für arzneimittelkonjugate
WO2015103549A1 (en)	2014-01-03	2015-07-09	The United States Of America, As Represented By The Secretary Department Of Health And Human Services	Neutralizing antibodies to hiv-1 env and their use
CA2930154A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CN105873616B (zh)	2014-01-03	2020-06-05	豪夫迈·罗氏有限公司	共价连接的多肽毒素-抗体缀合物
MX373097B (es)	2014-01-03	2020-04-27	Hoffmann La Roche	Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
US10323083B2 (en)	2014-01-15	2019-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Agents that specifically bind matrilin-3 and their use
AU2015206370A1 (en)	2014-01-16	2016-07-07	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10023892B2 (en)	2014-05-27	2018-07-17	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015112909A1 (en)	2014-01-24	2015-07-30	Genentech, Inc.	Methods of using anti-steap1 antibodies and immunoconjugates
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
CN111499741A (zh)	2014-02-12	2020-08-07	豪夫迈·罗氏有限公司	抗锯齿蛋白1抗体及使用方法
PE20161171A1 (es)	2014-02-21	2016-11-08	Genentech Inc	Anticuerpos bioespecificos anti-il-13/il-17 y sus usos referencia cruzada a solicitudes relacionadas
DK3122757T3 (da)	2014-02-28	2023-10-09	Hangzhou Dac Biotech Co Ltd	Ladede linkere og anvendelse deraf til konjugering
MX2016011637A (es)	2014-03-14	2017-04-13	Genentech Inc	Metodos y composiciones para secrecion de polipeptidos heterologos.
TW202330606A (zh)	2014-03-21	2023-08-01	美商艾伯維有限公司	抗-egfr抗體及抗體藥物結合物
JP6744855B2 (ja)	2014-03-21	2020-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗体のｉｎｖｉｖｏでの半減期のｉｎｖｉｔｒｏでの予測
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015148915A1 (en)	2014-03-27	2015-10-01	Academia Sinica	Reactive labelling compounds and uses thereof
AU2015237184B2 (en)	2014-03-28	2020-11-26	Xencor, Inc.	Bispecific antibodies that bind to CD38 and CD3
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
HUE046767T2 (hu)	2014-03-31	2020-03-30	Hoffmann La Roche	Anti-OX40 antitestek és alkalmazási eljárások
SG11201608192SA (en)	2014-04-11	2016-10-28	Medimmune Llc	Bispecific her2 antibodies
FR3020063A1 (fr)	2014-04-16	2015-10-23	Gamamabs Pharma	Anticorps humain anti-her4
BR112016024462B1 (pt)	2014-05-06	2022-12-27	Genentech, Inc	Métodos para a preparação de um anticorpo
BR112016025040A2 (en)	2014-05-23	2018-02-20	Genentech, Inc.	methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
US20150344585A1 (en)	2014-05-27	2015-12-03	Academia Sinica	Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (ja)	2014-05-27	2022-05-06	アカデミアシニカ	抗ｈｅｒ２糖操作抗体群およびその使用
CN107041139A (zh)	2014-05-28	2017-08-11	艾更斯司股份有限公司	海兔脯氨酸‑海兔异亮氨酸肽的衍生物
CN106714829A (zh)	2014-05-28	2017-05-24	中央研究院	抗TNF‑α醣抗体及其用途
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
EP3164419B1 (de)	2014-06-26	2024-07-24	F. Hoffmann-La Roche AG	Anti-brdu-antikörper und verfahren zur verwendung
CN107074948B (zh)	2014-07-11	2022-01-28	根马布股份公司	结合axl的抗体
EP3166627A1 (de)	2014-07-11	2017-05-17	Genentech, Inc.	Notch-signalweghemmung
US20160060360A1 (en)	2014-07-24	2016-03-03	Xencor, Inc.	Rapid clearance of antigen complexes using novel antibodies
EP3473271B1 (de)	2014-07-31	2022-07-20	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Humane monoklonale antikörper gegen epha4 und deren verwendung
TWI751102B (zh)	2014-08-28	2022-01-01	美商奇諾治療有限公司	對ｃｄ１９具專一性之抗體及嵌合抗原受體
ES3034398T3 (en)	2014-08-28	2025-08-18	Bioatla Inc	Conditionally active chimeric antigen receptors for modified t-cells
TWI745275B (zh)	2014-09-08	2021-11-11	中央研究院	使用醣脂激活人類ｉＮＫＴ細胞
TWI758784B (zh)	2014-09-12	2022-03-21	美商建南德克公司	抗her2抗體及免疫結合物
CA2957354A1 (en)	2014-09-12	2016-03-17	Genentech, Inc.	Cysteine engineered antibodies and conjugates
EP3191518B1 (de)	2014-09-12	2020-01-15	Genentech, Inc.	Anti-b7-h4-antikörper und immunkonjugate
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
KR102609034B1 (ko)	2014-09-17	2023-12-01	자임워크스 비씨 인코포레이티드	세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
WO2016049214A1 (en)	2014-09-23	2016-03-31	Genentech, Inc.	METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
AU2015324924B2 (en)	2014-10-01	2021-07-01	Medimmune, Llc	Method of conjugating a polypeptide
WO2016061389A2 (en)	2014-10-16	2016-04-21	Genentech, Inc.	Anti-alpha-synuclein antibodies and methods of use
GB201419185D0 (en)	2014-10-28	2014-12-10	Adc Biotechnology Ltd	Method of synthesising ADCs using affinity resin
CN107148283A (zh)	2014-10-31	2017-09-08	豪夫迈·罗氏有限公司	抗il‑17a和il‑17f交叉反应性抗体变体、包含其的组合物及其制备和使用方法
CN106796235B (zh)	2014-11-03	2021-01-29	豪夫迈·罗氏有限公司	用于检测t细胞免疫子集的测定法及其使用方法
US20160160290A1 (en)	2014-11-03	2016-06-09	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CA2961439A1 (en)	2014-11-05	2016-05-12	Genentech, Inc.	Anti-fgfr2/3 antibodies and methods using same
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
DK3215528T3 (da)	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
TWI705976B (zh)	2014-11-10	2020-10-01	美商建南德克公司	抗介白素-33抗體及其用途
EP3221364B1 (de)	2014-11-19	2020-12-16	Genentech, Inc.	Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
US11008403B2 (en)	2014-11-19	2021-05-18	Genentech, Inc.	Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
CN107001473B (zh)	2014-11-19	2021-07-09	豪夫迈·罗氏有限公司	抗-运铁蛋白受体抗体及使用方法
KR102689285B1 (ko)	2014-11-26	2024-07-31	젠코어 인코포레이티드	Ｃｄ3 및 종양 항원과 결합하는 이종이량체 항체
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
MA41019A (fr)	2014-11-26	2021-05-05	Xencor Inc	Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
ES2764111T3 (es)	2014-12-03	2020-06-02	Hoffmann La Roche	Anticuerpos multiespecíficos
AR102918A1 (es)	2014-12-05	2017-04-05	Genentech Inc	Anticuerpos anti-cd79b y métodos de uso
WO2016091891A1 (en)	2014-12-09	2016-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Human monoclonal antibodies against axl
CN107207591A (zh)	2014-12-10	2017-09-26	豪夫迈·罗氏有限公司	血脑屏障受体抗体及使用方法
WO2016098356A1 (en)	2014-12-19	2016-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
US10428155B2 (en)	2014-12-22	2019-10-01	Xencor, Inc.	Trispecific antibodies
US20160208018A1 (en)	2015-01-16	2016-07-21	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for ror1
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
WO2016118961A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Cancer markers and methods of use thereof
WO2016118191A1 (en)	2015-01-24	2016-07-28	Academia Sinica	Novel glycan conjugates and methods of use thereof
WO2016123412A1 (en)	2015-01-28	2016-08-04	Sorrento Therapeutics, Inc.	Antibody drug conjugates
HK1244512A1 (zh)	2015-02-04	2018-08-10	健泰科生物技术公司	突变型smoothened及其使用方法
CN112142844B (zh)	2015-02-05	2025-07-25	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US20180030095A1 (en)	2015-02-13	2018-02-01	George Robert Pettit	Silstatin compounds
WO2016138160A1 (en)	2015-02-24	2016-09-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US10227411B2 (en)	2015-03-05	2019-03-12	Xencor, Inc.	Modulation of T cells with bispecific antibodies and FC fusions
CA2978631C (en)	2015-03-09	2023-06-27	Agensys, Inc.	Antibody drug conjugates (adc) that bind to flt3 proteins
ES2768784T3 (es)	2015-03-23	2020-06-23	Bayer Pharma AG	Anticuerpos anti-CEACAM6 y usos de los mismos
WO2016165762A1 (en)	2015-04-15	2016-10-20	Ganymed Pharmaceuticals Ag	Drug conjugates comprising antibodies against claudin 18.2
PL3286315T3 (pl)	2015-04-24	2021-11-02	F. Hoffmann-La Roche Ag	Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
CA2980189A1 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
EP3778640A1 (de)	2015-05-01	2021-02-17	Genentech, Inc.	Maskierte anti-cd3-antikörper und verfahren zur verwendung
EP3091033A1 (de)	2015-05-06	2016-11-09	Gamamabs Pharma	Anti-human-her3-antikörper und verwendungen davon
JP7366518B2 (ja)	2015-05-06	2023-10-23	ヤンセンバイオテツク，インコーポレーテツド	前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
CN116196414A (zh)	2015-05-11	2023-06-02	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
US10591465B2 (en)	2015-05-12	2020-03-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and kits for labeling, detection and isolation of Foxp3+ regulatory T cells, isolated population of Foxp3+ regulatory T cells thus obtained and uses thereof
JP7048319B2 (ja)	2015-05-12	2022-04-05	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
ES2898023T3 (es)	2015-05-22	2022-03-03	Inst Nat Sante Rech Med	Fragmentos de anticuerpos monoclonales humanos que inhiben tanto la actividad catalítica de Cath-D como su unión al receptor LRP1
WO2016189091A1 (en)	2015-05-26	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en)	2015-05-28	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
PL3303632T5 (pl)	2015-05-29	2023-07-03	F. Hoffmann-La Roche Ag	Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
WO2016200835A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2985483A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies
ES2961346T3 (es)	2015-06-12	2024-03-11	Lentigen Tech Inc	Procedimiento para tratar cáncer con células T modificadas genéticamente
CN108026123B (zh)	2015-06-15	2021-02-05	杭州多禧生物科技有限公司	用于偶联的亲水链接体
CA2986928A1 (en)	2015-06-16	2016-12-22	Genentech, Inc.	Humanized and affinity matured antibodies to fcrh5 and methods of use
EP3310378B1 (de)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1-antikörper und verfahren zur verwendung
JP2018526972A (ja)	2015-06-16	2018-09-20	ジェネンテック，インコーポレイテッド	抗ｃｄ３抗体及び使用方法
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
JP6691144B2 (ja)	2015-06-24	2020-04-28	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
JP7021955B2 (ja)	2015-06-24	2022-03-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
CN108473573A (zh)	2015-06-29	2018-08-31	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于器官移植中
KR20180033523A (ko)	2015-07-10	2018-04-03	젠맵 에이/에스	암 치료를 위한 axl-특이적 항체-약물 접합체
FI3319936T3 (fi)	2015-07-12	2026-03-12	Hangzhou Dac Biotech Co Ltd	Silloituslinkkereitä soluun sitoutuvien molekyylien konjugoimiseksi
US9839687B2 (en)	2015-07-15	2017-12-12	Suzhou M-Conj Biotech Co., Ltd.	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
PH12018500203B1 (en)	2015-08-05	2023-02-22	Janssen Biotech Inc	Anti-cd154 antibodies and methods of using them
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3350224B1 (de)	2015-09-20	2024-06-19	The United States of America, as Represented By the Secretary, Department of Health and Human Services	Für fibroblastenwachstumsfaktor-rezeptor 4 (fgfr4) spezifische monoklonale antikörper und verfahren zu deren verwendung
UA125432C2 (uk)	2015-09-23	2022-03-09	Дженентек, Інк.	Оптимізовані варіанти анти-vegf антитіл
EP3352791B1 (de)	2015-09-24	2019-10-30	AbVitro LLC	Hiv-antikörperzusammensetzungen und verfahren zur verwendung
CN113912724B (zh)	2015-09-25	2025-03-14	豪夫迈·罗氏有限公司	抗tigit抗体和使用方法
KR102770238B1 (ko)	2015-09-30	2025-02-18	얀센 바이오테크 인코포레이티드	인간 cd40에 특이적으로 결합하는 작용성 항체 및 사용 방법
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3356406A1 (de)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung
MY192202A (en)	2015-10-02	2022-08-06	Hoffmann La Roche	Bispecific antibodies specific for pd1 and tim3
RS62450B1 (sr)	2015-10-02	2021-11-30	Hoffmann La Roche	Anti-pd1 antitela i postupci primene
AU2016335750B2 (en)	2015-10-07	2023-05-25	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
CN108779162B (zh)	2015-10-09	2021-12-07	美天施生物科技有限公司	嵌合抗原受体和使用方法
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
US10556953B2 (en)	2015-10-12	2020-02-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
WO2017066714A1 (en)	2015-10-16	2017-04-20	Compugen Ltd.	Anti-vsig1 antibodies and drug conjugates
JP6621919B2 (ja)	2015-10-16	2019-12-18	ジェネンテック，インコーポレイテッド	束縛ジスルフィド薬物コンジュゲート
WO2017067944A1 (en)	2015-10-19	2017-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
ES2904553T3 (es)	2015-10-30	2022-04-05	Hoffmann La Roche	Fragmentos de anticuerpo modificados con bisagra y procedimientos de preparación
HUE057837T2 (hu)	2015-11-03	2022-06-28	Janssen Biotech Inc	PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
CN108602884B (zh)	2015-11-08	2024-06-25	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
CN106674327A (zh) *	2015-11-10	2017-05-17	复旦大学	一种Dolastatin 10衍生物、其制备方法及应用
WO2017100372A1 (en)	2015-12-07	2017-06-15	Xencor, Inc.	Heterodimeric antibodies that bind cd3 and psma
IL313608A (en)	2015-12-09	2024-08-01	Hoffmann La Roche	Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
MA44072A (fr)	2015-12-17	2018-10-24	Janssen Biotech Inc	Anticorps se liant spécifiquement à hla-dr et leurs utilisations
RU2742606C2 (ru)	2015-12-18	2021-02-09	Чугаи Сейяку Кабусики Кайся	Антитела к с5 и способы их применения
CA3002422C (en)	2015-12-18	2024-04-16	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
US12115227B2 (en)	2016-01-13	2024-10-15	Genmab A/S	Formulation for antibody and drug conjugate thereof
CN108495653A (zh)	2016-01-27	2018-09-04	免疫医疗有限责任公司	用于制备具有定义的糖基化模式抗体的方法
WO2017132617A1 (en)	2016-01-27	2017-08-03	Sutro Biopharma, Inc.	Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
US11191821B2 (en)	2016-02-27	2021-12-07	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Peptide vaccine formulations and use thereof for inducing an immune response
EP3423112A4 (de)	2016-02-29	2020-02-26	Madrigal Pharmaceuticals, Inc.	Hsp9-inhibitor-wirkstoff-konjugate
CN114395624A (zh)	2016-02-29	2022-04-26	基因泰克公司	用于癌症的治疗和诊断方法
WO2017156192A1 (en)	2016-03-08	2017-09-14	Academia Sinica	Methods for modular synthesis of n-glycans and arrays thereof
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN114907483B (zh)	2016-03-22	2024-07-26	国家医疗保健研究所	人源化抗claudin-1抗体及其用途
JP7073266B2 (ja)	2016-03-25	2022-05-23	シージェンインコーポレイテッド	Ｐｅｇ化薬物リンカー及びその中間体を調製するためのプロセス
CA3056374A1 (en)	2016-04-13	2017-10-19	Orimabs Ltd.	Anti-psma antibodies and use thereof
EP3443004A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3-antikörper und verfahren zur verwendung
CN109154027A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
AU2017248644B2 (en)	2016-04-15	2019-10-31	Bioatla, Llc	Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
EP3889175A1 (de)	2016-05-02	2021-10-06	F. Hoffmann-La Roche AG	Der contorsbody - ein einkettiger targetbinder
WO2017196847A1 (en)	2016-05-10	2017-11-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
LT3455261T (lt)	2016-05-13	2022-11-10	Bioatla, Inc.	Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas
CN109313200B (zh)	2016-05-27	2022-10-04	豪夫迈·罗氏有限公司	用于表征位点特异性抗体-药物缀合物的生物分析性方法
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CA3059010A1 (en)	2016-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2017214182A1 (en)	2016-06-07	2017-12-14	The United States Of America. As Represented By The Secretary, Department Of Health & Human Services	Fully human antibody targeting pdi for cancer immunotherapy
CN109563167A (zh)	2016-06-08	2019-04-02	艾伯维公司	抗b7-h3抗体和抗体药物偶联物
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
BR112018075644A2 (pt)	2016-06-08	2019-04-09	Abbvie Inc.	anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2018015274A (es)	2016-06-08	2019-10-07	Abbvie Inc	Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PL3458479T4 (pl)	2016-06-08	2021-07-26	Abbvie Inc.	Przeciwciała anty-b7-h3 i koniugaty przeciwciało-lek
KR102838691B1 (ko)	2016-06-14	2025-07-25	젠코어 인코포레이티드	이중특이적 체크포인트 억제제 항체
KR102680483B1 (ko)	2016-06-17	2024-07-01	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
WO2018004338A1 (en)	2016-06-27	2018-01-04	Tagworks Pharmaceuticals B.V.	Cleavable tetrazine used in bio-orthogonal drug activation
CN116063545A (zh)	2016-06-28	2023-05-05	Xencor股份有限公司	结合生长抑素受体2的异源二聚抗体
WO2018007592A1 (en)	2016-07-08	2018-01-11	Genmab A/S	New dosage regimens for antibody drug conjugates based on anti-axl antibodies
KR20230107408A (ko)	2016-07-29	2023-07-14	주노 쎄러퓨티크스 인코퍼레이티드	항-cd19 항체에 대한 항-이디오타입 항체
CA3031559A1 (en)	2016-08-02	2018-02-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
MX2019001448A (es)	2016-08-05	2019-09-13	Chugai Pharmaceutical Co Ltd	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
RS64925B1 (sr)	2016-08-10	2023-12-29	Legend Biotech Ireland Ltd	Himerni antigenski receptori koji ciljaju bcma i postupci njihove upotrebe
TWI764917B (zh)	2016-08-22	2022-05-21	醣基生醫股份有限公司	抗體、結合片段及使用方法
EP3504239B1 (de)	2016-08-25	2024-05-29	F. Hoffmann-La Roche AG	Intervalldosierung eines anti-csf-1r-antikörpers in kombination mit makrophagenaktivierungsmittel
US10793632B2 (en)	2016-08-30	2020-10-06	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045325A1 (en)	2016-09-02	2018-03-08	Lentigen Technology, Inc.	Compositions and methods for treating cancer with duocars
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
US10517958B2 (en)	2016-10-04	2019-12-31	Zymeworks Inc.	Compositions and methods for the treatment of platinum-drug resistant cancer
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
US10550185B2 (en)	2016-10-14	2020-02-04	Xencor, Inc.	Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
CN110121508A (zh)	2016-10-25	2019-08-13	法国国家健康和医学研究院	与cd160跨膜同种型结合的单克隆抗体
US11555076B2 (en)	2016-10-29	2023-01-17	Genentech, Inc.	Anti-MIC antibodies and methods of use
EP3535291A1 (de)	2016-11-01	2019-09-11	Genmab B.V.	Polypeptidvarianten und verwendungen davon
KR20220147721A (ko)	2016-11-14	2022-11-03	항저우 디에이씨 바이오테크 씨오, 엘티디	결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
MX2019005438A (es)	2016-11-15	2019-08-16	Genentech Inc	Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
US11135307B2 (en)	2016-11-23	2021-10-05	Mersana Therapeutics, Inc.	Peptide-containing linkers for antibody-drug conjugates
EP3554561B1 (de)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137-bindende fibronectin-typ-iii-domänen
JP7350313B2 (ja)	2016-12-16	2023-09-26	ブルーフィンバイオメディシン，インコーポレイテッド	抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US11236171B2 (en)	2016-12-21	2022-02-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies specific for FLT3 and uses thereof
JP7304287B2 (ja)	2016-12-22	2023-07-06	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
ES2936803T3 (es)	2017-01-09	2023-03-22	Lentigen Tech Inc	Composiciones y métodos para tratar el cáncer con inmunoterapia antimesotelina
JP7341060B2 (ja)	2017-02-10	2023-09-08	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
MY197534A (en)	2017-02-10	2023-06-21	Genentech Inc	Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010295A (es)	2017-03-01	2019-11-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
WO2018175994A1 (en)	2017-03-24	2018-09-27	Seattle Genetics, Inc.	Process for the preparation of glucuronide drug-linkers and intermediates thereof
US10426797B2 (en)	2017-03-24	2019-10-01	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD33 immunotherapy
WO2018195302A1 (en)	2017-04-19	2018-10-25	Bluefin Biomedicine, Inc.	Anti-vtcn1 antibodies and antibody drug conjugates
KR102769634B1 (ko)	2017-04-27	2025-02-19	테사로, 인코포레이티드	림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
EP3625256A1 (de)	2017-05-19	2020-03-25	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
AR111963A1 (es)	2017-05-26	2019-09-04	Univ California	Método y moléculas
MY199715A (en)	2017-06-05	2023-11-20	Janssen Biotech Inc	Antibodies that specifically bind pd-1 and methods of use
JP7657440B2 (ja)	2017-06-12	2025-04-07	ブルーフィンバイオメディシン，インコーポレイテッド	抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
US20210403573A1 (en)	2017-06-22	2021-12-30	INSERM (Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
TW201905037A (zh)	2017-06-22	2019-02-01	美商梅爾莎納醫療公司	藥物攜帶聚合物支架及蛋白質聚合物藥物共軛物之製造方法
WO2019005208A1 (en)	2017-06-30	2019-01-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en)	2017-06-30	2019-01-03	Lentigen Technology, Inc.	Human monoclonal antibodies specific for cd33 and methods of their use
JP2020529832A (ja)	2017-06-30	2020-10-15	ゼンコアインコーポレイテッド	ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
US20200165347A1 (en)	2017-06-30	2020-05-28	Aslan Pharmaceuticals Pte Ltd	Method of treatment using il-13r antibody
AU2018304458B2 (en)	2017-07-21	2021-12-09	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
US20200207859A1 (en)	2017-07-26	2020-07-02	Sutro Biopharma, Inc.	Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CA3071624A1 (en)	2017-07-31	2019-02-07	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
EP3672611A4 (de)	2017-08-25	2021-07-14	Janssen Biotech, Inc.	Fcyrii-bindende fibronectin-typ-iii-domänen, deren konjugate und diese enthaltende multispezifische moleküle
EP4279086A3 (de)	2017-09-15	2024-02-28	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
KR20200051802A (ko)	2017-09-18	2020-05-13	서트로 바이오파마, 인크.	항-엽산 수용체 알파 항체 접합체 및 이의 용도
EP4279584A3 (de)	2017-10-16	2024-03-06	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd22-immuntherapie
WO2019078357A1 (ja)	2017-10-20	2019-04-25	中外製薬株式会社	細胞への分子の取り込みを測定する方法
JP2021500391A (ja)	2017-10-24	2021-01-07	マジェンタセラピューティクスインコーポレイテッドＭａｇｅｎｔａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｃｄ１１７＋細胞を減少させるための組成物及び方法
MX2020004100A (es)	2017-10-30	2020-07-24	Hoffmann La Roche	Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
SG11202003501XA (en)	2017-11-01	2020-05-28	Juno Therapeutics Inc	Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
PL3704146T3 (pl)	2017-11-01	2022-03-07	F. Hoffmann-La Roche Ag	Przeciwciało Contorsbody trifab
CN111295392A (zh)	2017-11-01	2020-06-16	豪夫迈·罗氏有限公司	Compbody–多价靶结合物
EP3703711A4 (de)	2017-11-03	2021-01-13	Lentigen Technology, Inc.	Zusammensetzungen und verfahren zur behandlung von krebs mit anti-ror1-immuntherapie
JP7544597B2 (ja)	2017-11-06	2024-09-03	ジェネンテック，インコーポレイテッド	がんの診断及び療法
US10981992B2 (en)	2017-11-08	2021-04-20	Xencor, Inc.	Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en)	2017-11-08	2022-04-26	Xencor, Inc.	Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019094709A1 (en)	2017-11-09	2019-05-16	Pettit George R	Betulastatin compounds
EP3710589A4 (de)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
GB201719646D0 (en)	2017-11-27	2018-01-10	Bivictrix Therapeutics Ltd	Therapy
CN119857155A (zh)	2017-11-29	2025-04-22	海德堡医药研究有限责任公司	用于耗尽cd5+细胞的组合物和方法
JP7350740B2 (ja)	2017-11-30	2023-09-26	バイエル・アクチエンゲゼルシヤフト	Ｉｌｄｒ２アンタゴニストおよびその組み合わせ
EP3498293A1 (de)	2017-12-15	2019-06-19	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
IL275426B2 (en)	2017-12-19	2025-03-01	Xencor Inc	Engineered il-2 fc fusion proteins
CN111954677A (zh)	2017-12-20	2020-11-17	莱蒂恩技术公司	用于用免疫治疗来治疗hiv/aids的组合物和方法
TWI817974B (zh)	2017-12-28	2023-10-11	日商中外製藥股份有限公司	細胞毒性誘導治療劑
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3740505A1 (de)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
PE20211116A1 (es)	2018-02-08	2021-06-23	Genentech Inc	Moleculas biespecificas de union al antigeno y metodos de uso
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
CN116327926A (zh)	2018-03-15	2023-06-27	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
EP3773911A2 (de)	2018-04-04	2021-02-17	Xencor, Inc.	Heterodimere antikörper, die das fibroblastenaktivierungsprotein binden
CR20250325A (es)	2018-04-13	2025-08-29	Genentech Inc	Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
WO2019204665A1 (en)	2018-04-18	2019-10-24	Xencor, Inc.	Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
US11505595B2 (en)	2018-04-18	2022-11-22	Xencor, Inc.	TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019212357A1 (en)	2018-05-04	2019-11-07	Tagworks Pharmaceuticals B.V.	Compounds comprising a linker for increasing transcyclooctene stability
US20210299286A1 (en)	2018-05-04	2021-09-30	Tagworks Pharmaceuticals B.V.	Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019266205B2 (en)	2018-05-07	2026-01-08	Genmab A/S	Methods of treating cancer with a combination of an anti-PD-1 antibody and an anti-tissue factor antibody-drug conjugate
BR112020022642A2 (pt)	2018-05-07	2021-02-17	Genmab A/S	método para tratar câncer em um indivíduo, e, estojo
CA3100005A1 (en)	2018-05-14	2019-11-21	Werewolf Therapeutics, Inc.	Activatable cytokine polypeptides and methods of use thereof
EP3794024B1 (de)	2018-05-14	2023-05-10	Werewolf Therapeutics, Inc.	Aktivierbare interleukin-2-polypeptide und verfahren zu ihrer verwendung
CN112513085B (zh)	2018-05-24	2024-06-18	詹森生物科技公司	Psma结合剂及其用途
EA202190094A1 (ru)	2018-06-29	2021-04-21	Бёрингер Ингельхайм Интернациональ Гмбх	Антитела против cd40 для применения в лечении аутоиммунного заболевания
CR20210047A (es)	2018-07-02	2021-05-21	Amgen Inc	Proteína de unión al antígeno anti-steap1
JP7554742B2 (ja)	2018-07-03	2024-09-20	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
EP3820909B1 (de)	2018-07-11	2023-03-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Monoklonaler antikörper zum nachweis des antiviralen arzneimittels emtricitabin (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidin)
WO2020014482A1 (en)	2018-07-12	2020-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Affinity matured cd22-specific monoclonal antibody and uses thereof
WO2020023561A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US12012463B2 (en)	2018-08-08	2024-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-2 and uses thereof
PE20210343A1 (es)	2018-08-10	2021-02-23	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
WO2020052542A1 (en)	2018-09-10	2020-03-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cll1 and constructs thereof
US20220047716A1 (en)	2018-09-17	2022-02-17	Sutro Biopharma, Inc.	Combination therapies with anti-folate receptor antibody conjugates
JP7618950B2 (ja)	2018-09-19	2025-01-22	インサーム（インスティテュートナショナルデラサンテエデラルシェルシェメディカル）	免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
KR20210063330A (ko)	2018-09-19	2021-06-01	제넨테크, 인크.	방광암에 대한 치료 및 진단 방법
CA3113058A1 (en)	2018-09-20	2020-03-26	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-cd123 immunotherapy
EP3626265A1 (de)	2018-09-21	2020-03-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-human-cd45rc-antikörper und verwendungen davon
CN113286607B (zh)	2018-09-26	2024-07-12	莱蒂恩技术公司	用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
CA3112989A1 (en)	2018-09-27	2020-04-02	Xilio Development, Inc.	Masked cytokine polypeptides
JP7612571B2 (ja)	2018-10-03	2025-01-14	ゼンコアインコーポレイテッド	Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
EP3873534A1 (de)	2018-10-29	2021-09-08	Mersana Therapeutics, Inc.	Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
MA54052A (fr)	2018-10-29	2022-02-09	Hoffmann La Roche	Formulation d'anticorps
TWI844571B (zh)	2018-10-30	2024-06-11	丹麥商珍美寶股份有限公司	使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP2022512860A (ja)	2018-11-06	2022-02-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
JP7583720B2 (ja)	2018-11-30	2024-11-14	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ３８免疫療法によりがんを処置するための組成物および方法
SG11202105689XA (en)	2018-12-03	2021-06-29	Agensys Inc	Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
MX2021006573A (es)	2018-12-06	2021-07-15	Genentech Inc	Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
JP2022513198A (ja)	2018-12-10	2022-02-07	ジェネンテック，インコーポレイテッド	Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
JP7609775B2 (ja)	2018-12-14	2025-01-07	インセルム（インスティチュートナショナルデラサンテエデラリシェルシェメディカル）	単離されたＭＨＣ由来ヒトペプチドおよびＣＤ８＋ＣＤ４５ＲＣｌｏｗＴｒｅｇの抑制機能を刺激し、かつ活性化するためのその使用
WO2020127411A1 (en)	2018-12-19	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020127968A1 (en)	2018-12-20	2020-06-25	Marino Stephen F	Protein-drug conjugate comprising a monomeric form of proteinase 3
JP2022514290A (ja)	2018-12-20	2022-02-10	ジェネンテック，インコーポレイテッド	改変抗体ｆｃおよび使用方法
SG11202106498XA (en)	2018-12-26	2021-07-29	Xilio Development Inc	Anti-ctla4 antibodies and methods of use thereof
EP3883608A1 (de)	2019-01-08	2021-09-29	The United States of America, as represented by the Secretary, Department of Health and Human Services	Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren
TWI852977B (zh)	2019-01-10	2024-08-21	美商健生生物科技公司	前列腺新抗原及其用途
US12122843B2 (en)	2019-01-22	2024-10-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	High affinity monoclonal antibodies targeting glypican-1 and methods of use
CA3126359A1 (en)	2019-01-22	2020-07-30	Genentech, Inc.	Immunoglobulin a antibodies and methods of production and use
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
AU2020215576A1 (en)	2019-01-29	2021-07-08	Juno Therapeutics, Inc.	Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN113710706A (zh)	2019-02-27	2021-11-26	豪夫迈·罗氏有限公司	用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
BR112021016955A2 (pt)	2019-03-01	2021-11-23	Xencor Inc	Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
CN113924103B (zh)	2019-03-06	2025-02-14	莱蒂恩技术公司	用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
MY206650A (en)	2019-03-14	2024-12-30	Genentech Inc	Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
JP7593939B2 (ja)	2019-04-19	2024-12-03	ジェネンテック，インコーポレイテッド	抗ｍｅｒｔｋ抗体及びその使用方法
BR112021020532A2 (pt)	2019-04-19	2022-03-15	Janssen Biotech Inc	Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
WO2020227105A1 (en)	2019-05-03	2020-11-12	Sutro Biopharma, Inc.	Anti-bcma antibody conjugates
JP7550794B2 (ja)	2019-05-14	2024-09-13	ジェネンテック，インコーポレイテッド	濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
CA3137512A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
AU2020275348A1 (en)	2019-05-15	2021-12-09	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
US11052112B2 (en)	2019-05-30	2021-07-06	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-BCMA immunotherapy
IL289094A (en)	2019-06-17	2022-02-01	Tagworks Pharmaceuticals B V	Tetrazines for increasing the speed and yield of the "click release" reaction
ES2981364T3 (es)	2019-06-17	2024-10-08	Tagworks Pharmaceuticals B V	Compuestos para liberación clic rápida y eficiente
MX2022000174A (es)	2019-07-02	2022-05-20	Us Health	Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
CR20220049A (es)	2019-07-10	2022-03-02	Chugai Pharmaceutical Co Ltd	Moléculas de unión a claudina-6 y usos de las mismas
JPWO2021010326A1 (de)	2019-07-12	2021-01-21
CR20220025A (es)	2019-07-26	2022-05-04	Janssen Biotech Inc	Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos
CN119409834A (zh)	2019-08-12	2025-02-11	北京恩瑞尼生物科技股份有限公司	用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
EP4013783A1 (de)	2019-08-15	2022-06-22	Janssen Biotech, Inc.	Materialien und verfahren für verbesserte einzelkettige variable fragmente
CR20220127A (es)	2019-09-27	2022-05-27	Genentech Inc	Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
WO2021064184A1 (en)	2019-10-04	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
AU2020365836A1 (en)	2019-10-18	2022-04-28	F. Hoffmann-La Roche Ag	Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
EP4031250A1 (de)	2019-10-22	2022-07-27	The United States of America, as represented by the Secretary, Department of Health and Human Services	Gegen b7h3 (cd276) gerichtete hochaffine nanokörper zur behandlung von multiplen soliden tumoren
EP3812008A1 (de)	2019-10-23	2021-04-28	Gamamabs Pharma	Amh-kompetitiver antagonistischer antikörper
WO2021091899A1 (en)	2019-11-04	2021-05-14	Genisphere, Llc	Brain-specific angiogenesis inhibitor 1 (bai1) antibodies and uses thereof
CA3155922A1 (en)	2019-11-06	2021-05-14	Huang Huang	Diagnostic and therapeutic methods for treatment of hematologic cancers
MX2022005222A (es)	2019-11-07	2022-06-08	Genmab As	Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TW202131954A (zh)	2019-11-07	2021-09-01	丹麥商珍美寶股份有限公司	利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
CN115175926A (zh)	2019-11-14	2022-10-11	狼人治疗公司	可激活细胞因子多肽及其使用方法
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US12570749B2 (en)	2019-12-06	2026-03-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
AU2020402752A1 (en)	2019-12-12	2022-06-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-drug conjugates specific for CD276 and uses thereof
IL293423A (en)	2019-12-13	2022-07-01	Genentech Inc	Anti-ly6g6d antibodies and methods of use
CR20220357A (es)	2019-12-27	2022-08-24	Chugai Pharmaceutical Co Ltd	Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
TW202144389A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh)	2020-02-14	2021-12-01	美商健生生物科技公司	在卵巢癌中表現之新抗原及其用途
WO2021178597A1 (en)	2020-03-03	2021-09-10	Sutro Biopharma, Inc.	Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
PE20230001A1 (es)	2020-03-13	2023-01-05	Janssen Biotech Inc	Materiales y metodos para la union de siglec-3/cd33
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en)	2020-03-19	2024-03-05	Genentech, Inc.	Isoform-selective anti-TGFβ antibodies and methods of use
EP4127724A1 (de)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutische und diagnostische verfahren für krebs
IL297541A (en)	2020-04-24	2022-12-01	Genentech Inc	Methods for using anti-cd79b immunoconjugates
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
WO2021231976A1 (en)	2020-05-14	2021-11-18	Xencor, Inc.	Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021275489A1 (en)	2020-05-20	2022-12-01	Centre National De La Recherche Scientifique - Cnrs -	Single domain antibodies and their use in cancer therapies
TWI907431B (zh)	2020-05-27	2025-12-11	美商健生生物科技公司	包含ｃｄ３抗原結合域之蛋白質及其用途
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
CA3181672A1 (en)	2020-06-18	2021-12-23	Shi Li	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
US11497770B2 (en)	2020-06-22	2022-11-15	Lentigen Technology, Inc.	Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
WO2022002940A1 (en)	2020-06-29	2022-01-06	Genmab A/S	Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
US12295997B2 (en)	2020-07-06	2025-05-13	Janssen Biotech, Inc.	Prostate neoantigens and their uses
CN115812149A (zh)	2020-07-13	2023-03-17	基因泰克公司	用于预测多肽免疫原性的基于细胞的方法
US20230296612A1 (en)	2020-07-29	2023-09-21	Chugai Seiyaku Kabushiki Kaisha	Method for measuring pharmacokinetics of agent labeled with non-radioactive substance
AU2021317111A1 (en)	2020-07-29	2023-03-30	Janssen Biotech, Inc.	Proteins comprising HLA-G antigen binding domains and their uses
WO2022029080A1 (en)	2020-08-03	2022-02-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
KR20230095918A (ko)	2020-08-05	2023-06-29	주노 쎄러퓨티크스 인코퍼레이티드	Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
CN115836122A (zh)	2020-08-07	2023-03-21	基因泰克公司	用于预测多肽免疫原性的基于t细胞的方法
EP4192854A1 (de)	2020-08-07	2023-06-14	Genentech, Inc.	Flt3-ligandenfusionsproteine und verfahren zur verwendung
CN112062855B (zh)	2020-08-26	2024-08-30	北京天诺健成医药科技有限公司	一种含有衔接器的药物治疗剂的开发和应用
WO2022061061A1 (en)	2020-09-21	2022-03-24	Boehringer Ingelheim International Gmbh	Use of anti-cd40 antibodies for treatment of inflammatory conditions
TWI836278B (zh)	2020-10-05	2024-03-21	美商建南德克公司	用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
EP4228693A4 (de)	2020-10-13	2024-12-18	Janssen Biotech, Inc.	Biotechnologisch hergestellte t-zell-vermittelte immunität, materialien und andere verfahren zur modulation eines clusters der differenzierung iv und/oder viii
WO2022079270A1 (en)	2020-10-16	2022-04-21	Université D'aix-Marseille	Anti-gpc4 single domain antibodies
KR20230110523A (ko)	2020-10-22	2023-07-24	얀센 바이오테크 인코포레이티드	델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도
US20230391852A1 (en)	2020-10-26	2023-12-07	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022098628A2 (en)	2020-11-04	2022-05-12	Genentech, Inc.	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko)	2020-11-04	2023-06-28	제넨테크, 인크.	항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
MX2023005132A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
JP2023548555A (ja)	2020-11-05	2023-11-17	レンティジェン・テクノロジー・インコーポレイテッド	抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
CN118878693A (zh)	2020-11-23	2024-11-01	康诺亚生物医药科技（成都）有限公司	一种双特异性抗体及其用途
EP4251187A4 (de)	2020-11-25	2025-09-10	Xilio Dev Inc	Tumorspezifische spaltbare linker
CN114573703A (zh)	2020-12-02	2022-06-03	康诺亚生物医药科技（成都）有限公司	一种t细胞衔接器治疗剂的开发和应用
IL303349A (en)	2020-12-02	2023-08-01	Shanghai Henlius Biotech Inc	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
CN114573702A (zh)	2020-12-02	2022-06-03	康诺亚生物医药科技（成都）有限公司	一种新型肿瘤衔接器治疗药物的开发和应用
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
MX2023007133A (es)	2020-12-17	2023-06-27	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos.
GB202020572D0 (en)	2020-12-23	2021-02-03	Bivictrix Therapeutics Ltd	Novel methods of therapy
GB202020573D0 (en)	2020-12-23	2021-02-03	Bivictrix Therapeutics Ltd	Novel methods of therapy
CN114685657B (zh)	2020-12-31	2024-08-16	康诺亚生物医药科技（成都）有限公司	一种功能增强型抗体阻断剂的开发及其应用
JP2024505428A (ja)	2021-01-14	2024-02-06	アンスティテュキュリー	Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
WO2022162518A2 (en)	2021-01-28	2022-08-04	Janssen Biotech, Inc.	Psma binding proteins and uses thereof
IL305181A (en)	2021-02-15	2023-10-01	Takeda Pharmaceuticals Co	Cell therapy compositions and methods for modulating tgf-b signaling
JP2024506590A (ja)	2021-02-16	2024-02-14	グリコス・フィンランド・オーワイ	リンカー－ペイロードおよびそのコンジュゲート
TW202317612A (zh)	2021-03-01	2023-05-01	美商艾希利歐發展股份有限公司	用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
AU2022230384A1 (en)	2021-03-01	2023-09-07	Xilio Development, Inc.	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
KR20240012352A (ko)	2021-03-23	2024-01-29	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	T 세포 림프종의 진단 및 치료 방법
AR125212A1 (es)	2021-03-24	2023-06-28	Janssen Biotech Inc	Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
IL306103A (en)	2021-03-24	2023-11-01	Janssen Biotech Inc	The antibody targets CD22 and CD79B
US12384843B2 (en)	2021-03-30	2025-08-12	Bayer Aktiengesellschaft	Anti-semaphorin 3A antibodies
WO2022214681A1 (en)	2021-04-09	2022-10-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of anaplastic large cell lymphoma
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
WO2022232612A1 (en)	2021-04-29	2022-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lassa virus-specific nanobodies and methods of their use
WO2022228706A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
KR20240004659A (ko)	2021-04-30	2024-01-11	셀진 코포레이션	감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
MX2023013264A (es)	2021-05-12	2023-11-30	Genentech Inc	Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
EP4342984A4 (de)	2021-05-19	2025-04-23	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur vorhersage der in-vivo-pharmazekinetik eines moleküls
JP2024521187A (ja)	2021-05-28	2024-05-28	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	ガンの治療のための組み合わせ療法
EP4155321A1 (de)	2021-06-04	2023-03-29	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2-antikörper und verwendungen davon
US20240270851A1 (en)	2021-06-09	2024-08-15	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Cross species single domain antibodies targeting pd-l1 for treating solid tumors
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
IL309115A (en)	2021-06-25	2024-02-01	Chugai Pharmaceutical Co Ltd	Anti-CTLA-4 antibodies
IL309405A (en)	2021-06-29	2024-02-01	Seagen Inc	Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
US11807685B2 (en)	2021-08-05	2023-11-07	The Uab Research Foundation	Anti-CD47 antibody and uses thereof
US20240336697A1 (en)	2021-08-07	2024-10-10	Genentech, Inc.	Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN118176213B (zh)	2021-08-27	2025-09-23	詹森生物科技公司	抗psma抗体及其用途
EP4396229A1 (de)	2021-09-02	2024-07-10	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Anti-cecam6-antikörper mit reduzierten nebenwirkungen
MX2024002571A (es)	2021-09-03	2024-03-20	Toray Industries	Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20240099150A (ko)	2021-09-06	2024-06-28	베락사 바이오테크 게엠베하	진핵생물에서의 유전자 코드 확장을 위한 신규 아미노아실-tRNA 합성효소 변이체
WO2023041717A1 (en)	2021-09-16	2023-03-23	Aboleris Pharma	Anti-human cd45rc binding domains and uses thereof
EP4405392A1 (de)	2021-09-24	2024-07-31	Janssen Biotech, Inc.	Proteine mit cd20-bindenden domänen und verwendungen davon
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
EP4412713A1 (de)	2021-10-05	2024-08-14	GlaxoSmithKline Intellectual Property Development Ltd	Kombinationstherapien zur behandlung von krebs
US20240404622A1 (en)	2021-10-08	2024-12-05	Chugai Seiyaku Kabushiki Kaisha	Method for preparing prefilled syringe formulation
JP2024541058A (ja)	2021-11-03	2024-11-06	ハンジョウディーエーシーバイオテックシーオー．，エルティディ．	抗体の特異的共役
WO2023091887A1 (en)	2021-11-16	2023-05-25	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
EP4436669A1 (de)	2021-11-22	2024-10-02	Janssen Biotech, Inc.	Zusammensetzungen mit verbesserten multispezifischen bindemitteln für eine immunantwort
JP2024543916A (ja)	2021-11-25	2024-11-26	ヴェラクサバイオテックゲーエムベーハー	遺伝暗号拡張を利用した部位特異的結合によって調製された改良された抗体ペイロード複合体（ａｐｃ）
ES3039688T3 (en)	2021-11-25	2025-10-23	Veraxa Biotech Gmbh	Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
KR20240119102A (ko)	2021-12-08	2024-08-06	유럽피안 몰레큘러 바이올로지 래보러토리	표적화 접합체의 제조를 위한 친수성 테트라진-관능화 페이로드
US20250051440A1 (en)	2021-12-14	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
AU2022411573A1 (en)	2021-12-17	2024-06-27	Shanghai Henlius Biologics Co., Ltd.	Anti-ox40 antibodies and methods of use
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
UY40097A (es)	2022-01-07	2023-07-14	Johnson & Johnson Entpr Innovation Inc	Materiales y métodos de proteínas de unión a il-1b
EP4472740A1 (de)	2022-01-31	2024-12-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cd38 als biomarker und biotarget bei t-zell-lymphomen
AU2023221765B2 (en)	2022-02-15	2024-09-19	Tagworks Pharmaceuticals B.V.	Masked il12 protein
GB202202170D0 (en)	2022-02-17	2022-04-06	Bivictrix Ltd	Novel methods of therapy
GB202202171D0 (en)	2022-02-17	2022-04-06	Bivictrix Ltd	Novel methods of therapy
US11590169B1 (en)	2022-03-02	2023-02-28	Lentigen Technology, Inc.	Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en)	2022-03-02	2023-10-26	Lentigen Technology, Inc.	Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2023180353A1 (en)	2022-03-23	2023-09-28	F. Hoffmann-La Roche Ag	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
AU2022450448A1 (en)	2022-04-01	2024-10-10	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4508432A1 (de)	2022-04-11	2025-02-19	Institut National de la Santé et de la Recherche Médicale	Verfahren zur diagnose und behandlung von t-zell-malignitäten
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
US20230406930A1 (en)	2022-04-13	2023-12-21	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
WO2023198874A1 (en)	2022-04-15	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of t cell-lymphomas
IL316289A (en)	2022-04-29	2024-12-01	Purinomia Biotech Inc	Methods and compositions for treating diseases and disorders driven by eosinophils
US20230346862A1 (en)	2022-05-02	2023-11-02	Athanor Biosciences, Inc.	Cancer eradicating - bio-nanoparticles (ce-bnp)
JP2025515166A (ja)	2022-05-06	2025-05-13	ジェンマブエー／エス	抗組織因子抗体－薬物コンジュゲートを用いたがんの治療方法
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CA3257760A1 (en)	2022-06-07	2023-12-14	Genentech, Inc.	PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
WO2024003310A1 (en)	2022-06-30	2024-01-04	Institut National de la Santé et de la Recherche Médicale	Methods for the diagnosis and treatment of acute lymphoblastic leukemia
JP2025525445A (ja)	2022-06-30	2025-08-05	ストロバイオファーマインコーポレーテッド	抗ｒｏｒ１抗体及び抗体コンジュゲート、抗ｒｏｒ１抗体又は抗体コンジュゲートを含む組成物、並びに抗ｒｏｒ１抗体及び抗体コンジュゲートを作製及び使用する方法
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024013723A1 (en)	2022-07-15	2024-01-18	Pheon Therapeutics Ltd	Antibody drug conjugates that bind cdcp1 and uses thereof
AU2023309556A1 (en)	2022-07-19	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
EP4558823A1 (de)	2022-07-22	2025-05-28	Institut National de la Santé et de la Recherche Médicale	Garp als biomarker und biotarget bei t-zell-malignitäten
AU2023314413A1 (en)	2022-07-28	2025-02-13	Lentigen Technology, Inc.	Chimeric antigen receptor therapies for treating solid tumors
WO2024023283A1 (en)	2022-07-29	2024-02-01	Institut National de la Santé et de la Recherche Médicale	Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
CA3265857A1 (en)	2022-08-26	2024-02-29	Lentigen Technology, Inc.	COMPOSITIONS AND METHODS OF CANCER TREATMENT BY ALL-HUMAN ANTI-CD20/CD19 IMMUNOTHERAPY
JP2025531738A (ja)	2022-09-01	2025-09-25	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法及び診断方法
IL320221A (en)	2022-10-12	2025-06-01	Tagworks Pharmaceuticals B V	Strained bicyclo-nonanes
EP4602372A1 (de)	2022-10-12	2025-08-20	Institut National de la Santé et de la Recherche Médicale	Cd81 als biomarker und biotarget bei t-zell-malignitäten
IL320355A (en)	2022-10-25	2025-06-01	Genentech Inc	Therapeutic and diagnostic methods for multiple myeloma
WO2024102948A1 (en)	2022-11-11	2024-05-16	Celgene Corporation	Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
WO2024129778A2 (en)	2022-12-13	2024-06-20	Juno Therapeutics, Inc.	Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024153789A1 (en)	2023-01-20	2024-07-25	Basf Se	Stabilized biopolymer composition, their manufacture and use
EP4662313A1 (de)	2023-02-06	2025-12-17	Institut National de la Santé et de la Recherche Médicale	Anreicherung von genetisch modifizierten hämatopoietischen stammzellen durch multiplex-baseneditierung
WO2024170543A1 (en)	2023-02-14	2024-08-22	Institut National de la Santé et de la Recherche Médicale	Anti-cd44 antibodies and uses thereof
KR20250169530A (ko)	2023-03-10	2025-12-03	태그웍스 파마슈티컬스 비.브이.	개선된 t-링커를 갖는 트랜스-사이클로옥텐
EP4683673A2 (de)	2023-03-22	2026-01-28	Salubris Biotherapeutics, Inc.	Anti-5t4-antigenbindende domänen, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
EP4698225A1 (de)	2023-04-21	2026-02-25	GlaxoSmithKline Intellectual Property Development Limited	Auf zytotoxizität abzielende chimäre für antikörper-wirkstoff-konjugate und bispezifische antikörper
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024236156A1 (en)	2023-05-17	2024-11-21	Institut National de la Santé et de la Recherche Médicale	Anti-cathepsin-d antibodies
IL324958A (en)	2023-06-08	2026-01-01	Genentech Inc	Macrophage signatures for diagnostic and therapeutic approaches for lymphoma
WO2025014896A1 (en)	2023-07-07	2025-01-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Humanized 40h3 antibody
AU2024295016A1 (en)	2023-07-20	2026-02-05	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
CN121646574A (zh)	2023-07-27	2026-03-10	维拉克萨生物技术有限责任公司	亲水性反式环辛烯(hyTCO)化合物、含有该化合物的构建体和缀合物
WO2025027529A1 (en)	2023-07-31	2025-02-06	Advesya	Anti-il-1rap antibody drug conjugates and methods of use thereof
GB202312576D0 (en)	2023-08-17	2023-10-04	Bivictrix Ltd	A compound comprising a first and second antibody or antigen-binding fragment and methods of conjugating the same
GB202312575D0 (en)	2023-08-17	2023-10-04	Bivictrix Ltd	Bispecific antibodies
WO2025056807A1 (en)	2023-09-15	2025-03-20	Basf Se	Stabilized biopolymer composition, their manufacture and use
GB202314424D0 (en)	2023-09-20	2023-11-01	Cambridge Entpr Ltd	A conjugate
US12540197B2 (en)	2023-10-13	2026-02-03	Sutro Biopharma, Inc.	Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025120015A1 (en)	2023-12-06	2025-06-12	Institut National de la Santé et de la Recherche Médicale	Cd5 targeting antibodies with depleting and t or b-cell activation effects
TW202530255A (zh)	2023-12-15	2025-08-01	法商亞維西亞有限公司	抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Antibody drug conjugates and uses thereof
WO2025171238A1 (en)	2024-02-07	2025-08-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
GB202402048D0 (en)	2024-02-14	2024-03-27	Bivictrix Ltd	Therapeutic antibodies
GB202402046D0 (en)	2024-02-14	2024-03-27	Bivictrix Ltd	Therapeutic antibodies
WO2025174248A1 (en)	2024-02-16	2025-08-21	Tagworks Pharmaceuticals B.V.	Trans-cyclooctenes with "or gate" release
EP4624494A1 (de)	2024-03-29	2025-10-01	Institut Curie	Her2-einzeldomänenantikörper und verwendungen davon
WO2025223455A1 (en)	2024-04-24	2025-10-30	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.	Anti-ptk7/b7h3 antibodies and uses thereof
WO2025238052A1 (en)	2024-05-15	2025-11-20	Institut National de la Santé et de la Recherche Médicale	Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2025250825A1 (en)	2024-05-30	2025-12-04	Sutro Biopharma, Inc.	Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025248500A1 (en)	2024-05-31	2025-12-04	Janssen Biotech, Inc.	Antibody drug conjugates that target enpp3
US20260000765A1 (en)	2024-06-27	2026-01-01	Lentigen Technology, Inc.	CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR TREATING CANCER WITH IL7Fc ARMORED CAR-T CELLS
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026043376A1 (en)	2024-08-22	2026-02-26	Tagworks Pharmaceuticals B.V.	Trans-cyclooctene formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4978744A (en) *	1989-01-27	1990-12-18	Arizona Board Of Regents	Synthesis of dolastatin 10

1993
- 1993-01-26 US US08/009,296 patent/US5780588A/en not_active Expired - Fee Related
1994
- 1994-01-20 JP JP6032795A patent/JPH08119990A/ja active Pending
- 1994-01-24 AT AT94300495T patent/ATE161270T1/de not_active IP Right Cessation
- 1994-01-24 EP EP94300495A patent/EP0612762B1/de not_active Expired - Lifetime
- 1994-01-24 DE DE69407322T patent/DE69407322T2/de not_active Expired - Fee Related
- 1994-01-25 CA CA002114156A patent/CA2114156C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69407322T2 (de)	1998-06-04
CA2114156A1 (en)	1994-07-27
DE69407322D1 (de)	1998-01-29
CA2114156C (en)	2001-01-02
EP0612762A1 (de)	1994-08-31
US5780588A (en)	1998-07-14
JPH08119990A (ja)	1996-05-14
EP0612762B1 (de)	1997-12-17

Legal Events

Date	Code	Title	Description
1998-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE161270T1 (de)	1998-01-15	Aufklärung und synthese von ausgewählten pentapeptiden
EP0787009A4 (de)	1999-09-22	Krebs hemmende peptide
GR3018612T3 (en)	1996-04-30	Polyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides.
DE69425292D1 (de)	2000-08-24	Entzündungshemmendes und analgetisches äusserliches Pflaster-Präparat
NO843836L (no)	1985-03-27	Terapeutisk aktive sulfamatderivater
ATE243203T1 (de)	2003-07-15	Thienyl-, furyl-, pyrrolyl- und biphenylsulfonamide und derivate zur modulation der endothelin-aktivität
DE69627704T2 (de)	2004-01-29	Protegrine
ATE209215T1 (de)	2001-12-15	Protegrine
MX9801716A (es)	1998-05-31	Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
ID27285A (id)	2001-03-22	Turunan benzamida untuk pengobatan penyakit yang diperantarai oleh sitokina
IL108382A0 (en)	1994-04-12	Amino acid derivatives, their preparation and pharmaceutical compositions containing them
DE69610709D1 (de)	2000-11-23	N-aroyl-glycin-hydroxamsäure-derivate und verwandte verbindungen
BR0309558A (pt)	2005-03-01	Derivados de quinazolina e medicamentos
RU94044534A (ru)	1996-10-27	Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции
PT649846E (pt)	2002-06-28	Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
ES8103027A1 (es)	1981-02-16	Un procedimiento para la preparacion de un polipeptido
RU94022277A (ru)	1996-04-20	Новые 19-норстероиды, имеющие в положении 11 - бета феноксиалкилсульфонамидную или феноксиалкилсульфонилкарбамидную цепь, метод и промежуточные продукты их получения, и содержащая их фармацевтическая композиция
ATE356814T1 (de)	2007-04-15	Heterozyclische verbindungen, ihr herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen
DK0529410T3 (da)	1998-05-11	Antibiotikum GE 2270 faktor C2a
RU94046464A (ru)	1996-09-10	Новые биологически активные n-ацилпролилдипептиды, обладающие антиамнезийным, антигипоксийным и анорексигенным эффектами, способ их получения и содержащие их фармацевтический состав и лекарство
FI860074A0 (fi)	1986-01-08	Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
DE69224613D1 (de)	1998-04-09	Peptide, Herstellung und deren Verwendung
DE69412612D1 (de)	1998-09-24	Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
RU94045890A (ru)	1996-09-10	Трициклические соединения-антагонисты тахикинина, их получение и фармацевтические композиции, содержащие такие соединения
ATE192650T1 (de)	2000-05-15	Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit